Hoffmann-la Roche Inc.

Global Alliance for Tb Drug Development

F. Hoffmann-la Roche Ag

Nader Fotouhi

Paul Gillespie

Sherrie Lynn Pietranico-Cole

Jefferson Wright Tilley

Robert W Guthrie

Weiya Yun

Robert Alan Goodnow, Jr

Binh Vu

Takushi Kaneko

Stephen Evan Webber

Allen John Lovey

Norman Kong

Waleed Danho

Kshitij Chhabilbhai Thakkar

Gregory Jay Haley

Emily Aijun Liu

Wajiha Khan

Klaus B Simonsen

Nancy-Ellen Haynes

Kevin Richard Guertin

Christopher Blair Cooper

Nathan Robert Scott

Rebecca Taub

Agnieszka Kowalczyk

Joseph Swistok

George Kenneth Ehrlich

David Charles Fry

John Guilfoyle Mullin, Jr

Anish A Konkar

Karin Conde-Knape

Cristina Martha Rondinone

Michael Paul Myers

Li Chen

Yimin Qian

Matthew Michael Hamilton

Shawn David Erickson

Alexander Mayweg

Achyutharao Sidduri

Steven Gregory Mischke

Zhuming Zhang

Robert Francis Kester

Kang Le

Xin-Jie Chu

Romyr Dominique

Kyungjin Kim

John Frederick Boylan

Christophe Michoud

Steven Joseph Berthel

Lee Apostle McDermott

Lida Qi

Qi Qiao

Jianping Cai

Nicholas J S Huby

Dongfeng Zhang

Giuseppe Federico Weber

John Anthony Moliterni

Pamela Loreen Rossman

Qiang Zhang

Kevin W Anderson

Haihong Huang

Joseph Anthony Bilotta

Huifeng Niu

Hong Wang

Bruce Lester Banner

David Young Jackson

Yi Han

Francesca Milletti

Alexander V Mayweg

Binh Thanh Vu

Doongfeng Zhang

Robert Alan Goodnow Jr

Kevin William DrANDERSON

David C Fry

Anish Konkar

Rebecca Anne Taub

George Ehrlich

The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treatingand other microbial infections, either alone or in combination with other anti-infective treatments.

Substituted phenyloxazolidinones for antimicrobial therapy

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of tuberculosis. 

Heteroaryltrifluoroborate compounds for the treatment of mycobacterial infections

The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treatingand other microbial infections, either alone or in combination with other anti-infective treatments. 

The present invention provides compounds to disrupt the eIF4E-eIF4G interaction and pharmaceutically acceptable salts of such compounds. Generally, the compounds are cell-penetrating peptides which bind mammalian initiation factor eIF4E (CPP-eIF4E), wherein the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 7, 9-11, 12-26, 27-44 and 45-51. More preferably, the amino acid sequence comprises at least 9 to about 40 amino acids and the mammalian initiation factor eIF4E is human initiation factor eIF4E.

Cell penetrating peptides to target EIF4E

Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. X is 4-oxo-6-(1-piperazinyl)-3(4H)-quinazoline-acetic acid (Pqa). These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.

Neuropeptide-2 receptor (Y-2R) agonists and uses thereof

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, COPD.

[object Object]

and the pharmaceutically acceptable salts and esters thereof, wherein X, X, X, Y, Yand R are described herein inhibit the interaction of MDM2 protein with a p53-like peptide and hence have anti proliferative activity.

Chiral cis-imidazolines

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of obesity, hyperphagia, anxiety, depression and related disorders and diseases.

MCH receptor antagonists

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

Adamantyl-pyrazole carboxamides as inhibitors of 11&#x3b2;-hdroxysteroid dehydrogenase

There are provided compounds of the formula I wherein R, V, Vand Ring A are described herein. The compounds exhibit anticancer activity.

Cis-imidazolines

Pyrazolones as inhibitors of 11&#x3b2;-hydroxysteroid dehydrogenase

There are presented compounds of the formula or pharmaceutically acceptable salts thereof,wherein Y, Y, X, X, Xand R are as described in this application. These compounds are believed to inhibit MDM2-p53 interaction and as such the compounds will have anti-hyperproliferative cellular activity.

The invention is directed to compounds of formula (1) and pharmaceutically acceptable salts thereof, methods for the preparation thereof, and methods of use thereof.

Thiazolyl-benzimidazoles

A compound of formula 1a which is useful for treating reperfusion injury, and salts, prodrugs, and related compounds.

Diaminopropionic acid derivatives

Growing community of inventors

Basking Ridge, NJ, United States of America

Nader Fotouhi